Jacobio Pharma Partners with AstraZeneca in $2 Billion Pan-KRAS Inhibitor Deal
核心洞察
Jacobio Pharma (搜索) has entered a global exclusive licensing agreement with AstraZeneca for its Pan-KRAS (搜索) inhibitor JAB-23E73, with AstraZeneca receiving development and commercialization rights outside China.
The deal includes an upfront payment of $100 million to Jacobio, with potential milestone payments reaching up to $1.915 billion plus tiered royalties on net sales.
JAB-23E73 targets multiple KRAS (搜索) mutation subtypes and is currently in Phase I trials in China and the United States, showing early signs of anti-tumor activity.
Jacobio Pharma (搜索) has announced a strategic partnership with AstraZeneca for its proprietary Pan-KRAS (搜索) inhibitor JAB-23E73, marking one of the largest oncology licensing deals of the year. Under the agreement, AstraZeneca will receive exclusive development and commercialization rights outside of China, while both companies will jointly develop and commercialize the drug within the Chinese market.
Financial Terms and Structure
The licensing agreement provides Jacobio with an immediate upfront payment of $100 million, positioning the company for accelerated global development efforts. Beyond the initial payment, Jacobio is eligible for additional development and commercial milestone payments totaling up to $1.915 billion, along with tiered royalties on net sales achieved outside of China.
AstraZeneca will assume full responsibility for clinical development, regulatory submissions, and commercialization activities for JAB-23E73 in all territories outside China, while maintaining joint development responsibilities within the Chinese market alongside Jacobio.
Targeting KRAS Mutations
JAB-23E73 represents an innovative approach to targeting KRAS (搜索), the most frequently mutated oncogene in human cancers. The Pan-KRAS inhibitor was developed using Jacobio's induced allosteric drug discovery platform and is designed to target multiple KRAS mutation subtypes. KRAS mutations are present in approximately 23% of all cancer patients, making it a critical therapeutic target.
"KRAS (搜索) is one of the most important oncogenes in cancer, with KRAS-mutated tumours driving profound unmet need for patients with pancreatic, colorectal and lung cancers," said Matt Hellmann, Senior Vice President, Early Oncology and Precision Medicine, Oncology R&D at AstraZeneca.
Clinical Development Progress
JAB-23E73 is currently being evaluated in Phase I trials in both China and the United States, where early signs of anti-tumor activity have been observed. The drug's development represents a significant advancement in targeting KRAS (搜索)-driven cancers, which have historically been challenging to treat effectively.
Yinxiang Wang, Chairman and Co-CEO of Jacobio Pharma (搜索), emphasized the partnership's significance: "This collaboration marks a significant step forward as we bring our world-class programs to the global stage and maximize the value of our R&D innovation. We are committed to providing breakthrough treatments and improving survival for patients, including those with KRAS (搜索)-mutated cancers, across the world."
Strategic Implications
The agreement strengthens Jacobio's financial position and accelerates global development efforts while expanding the company's presence in the international oncology innovation ecosystem. AstraZeneca's involvement brings extensive global development and commercialization capabilities to advance JAB-23E73 through clinical trials and toward potential market approval.
Looking forward, Jacobio plans to continue exploring the KRAS (搜索) pathway, advancing antibody-drug conjugates (tADCs) with KRAS inhibitors as payloads, and developing differentiated drugs targeting additional KRAS mutation types. The company also intends to advance its immuno-oncology programs, including its STING (搜索)-based iADC platform.
The partnership positions both companies to potentially transform treatment outcomes for patients with KRAS (搜索)-mutated cancers across pancreatic, colorectal, and lung cancer (搜索) indications, addressing a significant unmet medical need in oncology.